Simcere Set For Hong Kong Relisting After New Venture Success
This article was originally published in PharmAsia News
China’s Simcere Pharmaceutical Group is planning to return to the public market in Hong Kong this year, three years after delisting from the New York Stock Exchange. The company is building out an open platform and innovation incubator to support life science start-ups.
Register for our free email digests: